What is Precigen?
Precigen Inc. is a discovery and clinical-stage biopharmaceutical firm dedicated to developing gene and cell therapies. Leveraging precision technology, the company targets complex diseases across critical areas including immuno-oncology, autoimmune disorders, and infectious diseases. Precigen operates through two primary segments: Biopharmaceuticals, focusing on its core therapeutic pipeline, and Exemplar, which likely supports its platform development and specialized applications. The company's focus on precision medicine positions it at the forefront of therapeutic innovation.
How much funding has Precigen raised?
Precigen has raised a total of $129.4M across 1 funding round:
Stock Offering
$129.4M
Stock Issuance/Offering (2021): $129.4M, investors not publicly disclosed
What's next for Precigen?
The substantial enterprise-level funding and recent strategic investment indicate a strong market confidence in Precigen's scientific approach and therapeutic potential. This capital infusion is expected to accelerate the company's clinical development programs, potentially enabling further expansion of its research into novel disease targets and the scaling of its manufacturing capabilities. The strategic nature of the recent financing suggests a focus on key partnerships or market entry initiatives, positioning Precigen for significant growth and impact in the biopharmaceutical sector.
See full Precigen company page
